Board of

Shlomo Ben-Haim


Professor Shlomo Ben-Haim, a renowned medical device entrepreneur, has an impressive record of co-founding companies and maximizing their value. He has held faculty appointments as a Professor of Medicine, Physiology and Biophysics at both Harvard University and the Technion – Israel Institute of Technology. Professor Ben-Haim’s education was in Medicine and Biophysics. He has published over 200 scientific papers in peer-reviewed journals, and is the recipient of a long list of prizes for his research and inventions. Professor Ben-Haim is the inventor of more than 550 patents and patent applications worldwide, including those for a navigated cardiac catheterization system and an implantable device for treating congestive heart failure and diabetes. Professor Ben-Haim is now focusing on building businesses in healthcare that improve patient health, and reduce total healthcare spending.

Simos Kedikoglou

Chief Executive Officer (CEO)

Dr. Simos Kedikoglou became our CEO in 2013 and serves on the Company’s Board of Directors. He was previously CEO of MedInvest, an Israeli Medical Technology Incubator overseeing 10 portfolio companies with responsibility for their clinical and commercial strategy, technology development and debt and equity financing. He has also served as Corporate Vice President of Business Development for Boston Scientific responsible for acquisitions, licensing and distribution deals in the US, Europe and Asia and an Associate Partner with McKinsey & Company in the US advising clients on acquisitions in pharmaceuticals and medical devices. Simos holds a Medical Degree from the University of Athens, Greece, an MBA with distinction from Harvard Business School as well as a Master’s in Public Health from Harvard University, and he is a CFA Charterholder.

John Bakewell


has served in senior executive roles for nearly three decades, building and executing business strategies for growth companies across the medical device, specialty pharma, diagnostics, and healthcare provider sectors while also serving on public and private company boards. He currently serves on the Boards of Directors of Treace Medical Concepts, Inc. (Nasdaq: TMCI), Neuronetics, Inc. (Nasdaq: STIM), and Xtant Medical Holdings (NYSE American: XTNT), and previously served on the Boards of Entellus Medical, Inc. (Nasdaq: ENTL), ev3, Inc. (Nasdaq: EVVV), Corindus Vascular Robotics, Inc. (Nasdaq: CVRS), and Keystone Dental, Inc. John served as Executive Vice President and Chief Financial Officer of Wright Medical Group, Inc. (Nasdaq: WMGI); Vice President, Finance and Administration and CFO of Cyberonics Inc. (Nasdaq: CYBX); Chief Financial Officer of Lantheus Holdings, Inc. (Nadaq: LNTH); Executive Vice President and Chief Financial Officer of RegionalCare Hospital Partners, Inc.; and Chief Financial Officer of Exact Sciences Corporation (Nasdaq: EXAS). Mr. Bakewell began his career as a CPA, serving with KPMG and Ernst & Young. He holds a bachelor’s degree in accounting from the University of Northern Iowa and is a certified public accountant (inactive).

Joseph H. Capper


most recently served as President and Chief Executive Officer of BioTelemetry, Inc, (formerly Nasdaq: BEAT), the successor to CardioNet, Inc., and Home Diagnostics, Inc. (Nasdaq: HDIX). Prior to Home Diagnostics, Joe was President and Chief Executive Officer of CCS Medical Inc., a private company. Earlier, Joe spent nine years with Bayer Corporation, ultimately becoming National Sales Director of the Diabetic Products Division, where he led a 180-person sales organization with responsibility for over $350 million in revenue. Joe also has a distinguished service record, having served in the U.S. Navy as a combat aviator and later as a congressional liaison. Joe received his undergraduate degree in accounting from West Chester University and an MBA in International Finance from George Washington University.

Heron Ho


Mr. Heron Ho is the Investment Director of Henderson (China) Investment as a management role for the family fund of Chairman Dr. Peter KK Lee of Henderson Land, one of Hong Kong’s largest business enterprises. Mr. Ho leads over tens of PE/VC investments for the fund including the med-tech and bio-tech portfolio companies: Impulse Dynamics, Huasky Biomedical, Abpro, Shockwave Medical, and CG Oncology.  Mr. Ho has more than 15 years of experience in asset management, M&A, PE/VC, and business development.  Prior to Henderson, Mr. Ho worked as investment principals for CMS Capital, GCL Capital and Tokio Marine Asset Management, specialized in private equity investments.  Mr. Ho holds an MBA degree with distinction from the Hong Kong University of Science and Technology (HKUST) Business School as well as a bachelor’s degree in Information Systems the University of Hong Kong, and he is a CFA Charterholder.​

Glenn P. Muir


A certified public accountant, was Chief Financial Officer of Hologic, Inc. (Nasdaq: HOLX) for twenty-six years, including the Company’s IPO in 1990. Glenn is currently a member of the Board of Directors and is the Audit Committee Chair at Repligen Corporation (Nasdaq: RGEN), Neuronetics, Inc. (Nasdaq: STIM), and at G1 Therapeutics, Inc. (Nasdaq: GTHX). His past board experience includes RainDance Technologies, Inc., Hologic, Inc. (Nasdaq: HOLX), ReWalk Robotics Ltd (Nasdaq: RWLK), and Vivid Technologies (Nasdaq: Vivid), Inc. Glenn graduated from the University of Massachusetts in Amherst and holds an MBA from Harvard University Graduate School of Business Administration and a master’s degree in taxation from Bentley College Graduate School of Business.

Antony Owers


Mr. Owers joined Impulse Dynamics N.V. in 2001 with responsibility for all aspects of the Curaçao-based company. In addition to these duties, he also serves as a non-executive director of Impulse Dynamics USA and chairs the Group Audit Committee. And for thirty years, Mr. Owers worked in the employment of the accounting firm KPMG, located in London, São Paulo, Brazil, and Curaçao — the latter as a senior audit partner for many years.

Moreover, Mr. Owers has been a Fellow of the Institute of Chartered Accountants in England and Wales since 1980 and was British Consul to the Dutch Caribbean Islands from 1997 – 2013. In addition to his duties with Impulse Dynamics and several other local and international companies in a financial investment capacity, he is treasurer of several charitable foundations in Curaçao, including the Red Cross. In 2016, King Willem-Alexander of The Netherlands named Mr. Owers a Knight of the Dutch Realm.

Daniel Scavilla


Dan Scavilla is the President and Chief Executive Officer of Globus Medical, Inc. (NYSE: GMED) and is also a member of the company’s Board of Directors. Mr. Scavilla began his career at Globus Medical as the Chief Financial Officer in May 2015. He then served as the Executive Vice President, Chief Commercial Officer and the President of Trauma. Prior to joining Globus, Mr. Scavilla spent 28 years in various positions within Johnson & Johnson, including serving as Chief Financial Officer, Global Vice President Finance & Business Operations of Johnson & Johnson Vision Care from February 2012 to December 2015, and as Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products, the infection prevention branch of Johnson & Johnson Medical Devices from October 2007 to January 2012. Other prior roles at Johnson & Johnson include financial management positions at McNeil Consumer Healthcare, Centocor Biologics, and Cilag Schaffhausen Operations in Switzerland.

Mr. Scavilla received a B.S. in Finance and Organizational Behavior from LaSalle University and holds an MBA in International Management from Temple University.

James R. Tobin


serves on the Boards of TransMedics, Inc. (Nasdaq: TMDX), where he is also Chairman, and Globus Medical, Inc. (NYSE: GMED). Jim previously served as President and Chief Executive Officer of Boston Scientific (NYSE: BSX) and Biogen (Nasdaq: BIIB), Chief Operating Officer of Baxter (NYSE: BAX), and was a lieutenant in the U.S. Navy. Jim holds an MBA from Harvard Business School and a bachelor’s degree from Harvard College.

Ray Yang


Mr. Ray Yang joined CITIC Group in 2011 and has been active in the global investment field. In his eight-year investment career, he has successfully instructed dozens of domestic and foreign companies in investment and divestment operations, such as United Imagining, Genomics, and Impulse Dynamics. Mr. Ray Yang holds a bachelor’s degree in engineering, a master’s degree in management science and engineering from Tsinghua University, and a master’s degree in engineering from the University of Aachen, Germany.